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Abstract
The fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder caused by
expansions of 55-200 CGG repeats in the 5’UTR of the FMR1 gene. These FMR1 premutation expansions have
relatively high frequency in the general population. To estimate the frequency of FMR1 premutations among
Portuguese males with non-familial, late-onset movement disorders of unknown etiology, we assessed CGG repeat
size in males with disease onset after the age of 50 and negative or unknown family history for late-onset
movement disorders, who were sent for SCA, HD, or PD genetic testing at a reference laboratory. The selected
patients had a primary clinical diagnosis based on one of the following cardinal features of FXTAS: ataxia, tremor,
or cognitive decline. A total of 86 subjects were genotyped for the CGG repeat in the FMR1 gene. We detected
one patient with an expansion in the premutation range. The frequency of FMR1 premutations was 1.9% (1/54) in
our group of patients with ataxia as the primary clinical feature, and 1.2% (1/86) in the larger movement disorders
group. In the family of the FXTAS case, premutation-transmitting females presented a history of psychiatric
symptoms, suggesting that, given the wide phenotypical expression of the premutation in females,
neuropsychiatric surveillance is necessary. In conclusion, genetic testing for FXTAS should be made available to
patients with adult-onset movement disorders to enable adequate genetic counseling to family members.
Findings
Expansions of a CGG repeat tract in the 5’UTR region
of the FMR1 gene causes the fragile X syndrome (FXS),
the most common inherited cause of mental retardation.
FXS is an X-linked disorder, characterized by moderate
to severe mental impairment, facial dysmorphism and
behavioral abnormalities in males, and by milder symp-
toms in some carrier females [1]. Full mutations (more
than 200 CGGs) cause FXS, as they lead to loss of func-
tion due to gene silencing mediated by abnormal methy-
lation patterns [2,3]. Normal alleles range in length from
5 to 44 triplets, and repeats of 45-54 CGGs are “grey
zone alleles” of unknown biological significance [4]. Pre-
mutations range from 55 to 200 CGGs and have been
associated with two different phenotypes: females are at
a higher risk for premature ovarian insufficiency (POI)
[5]; whereas males may be affected by the fragile X-asso-
ciated tremor/ataxia syndrome (FXTAS) [6,7].
FXTAS is characterized by progressive cerebellar
ataxia, tremor, and parkinsonism with bradikynesia and
rigidity; other symptoms may include cognitive decline
and peripheral neuropathy [8]. Neuroradiological find-
ings show generalized brain atrophy with white matter
lesions in the middle cerebellar peduncle [9,10]. Clinical
criteria for FXTAS were proposed by Hagerman et al.
[11]: presence of a FMR1 premutation, one major clini-
cal sign (gait ataxia or intention tremor), and one major
finding on neuroimaging (white matter lesions in middle
cerebellar peduncles). Histopathology of FXTAS post-
mortem brains revealed loss of Purkinje cells in the cer-
ebellum, and presence of eosinophilic intranuclear
inclusions in neurons and astrocytes of the cortex [12].
The pathogenic mechanism of FXTAS seems to be dif-
ferent from that of FXS: abnormal methylation does not
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occur with premutation and, therefore, a loss of function
mechanism is unlikely. Instead, it appears to be asso-
ciated with toxic RNA species containing long CGG
tracts [13].
Penetrance of FXTAS in males carrying FMR1 premu-
tations increases from 17% in the sixth decade to 75%
after the age of 80. FXTAS in females has been reported
[14,15], but appears to be rare. Though only 1/4000
men have the full mutation, frequency of premutations
is much greater: 1/1000 in Caucasian males [16]. The
high frequency of FMR1 premutations in the general
population was taken as an indication that they could
represent a major cause of non-familial cases of late-
onset ataxia. A review of the literature reported that the
frequency of FMR1 premutations, in all combined ataxia
cases, was 1.3% in men and 0.24% in women [17]. As
ataxia in FXTAS is often associated with tremor and/or
cognitive decline, it is plausible that some cases of
FXTAS could present for testing with a clinical diagno-
sis other than cerebellar ataxia; therefore, other move-
ment disorders have also been screened for FMR1
premutations. The combination of all studies published
up to 2008, in patients with movement disorders other
than ataxia (including essential tremor, parkinsonism,
and multiple system atrophy), gives a total frequency of
CGG repeat length in the FXTAS range of 0.37%, higher
than the overall population rate [17].
Here, we present the first study on the frequency of
FMR1 premutations in a sample of Portuguese males
sent for genetic testing, with late-onset movement disor-
ders characterized by one or more of the FXTAS cardi-
nal clinical features (ataxia, tremor, or cognitive
decline). Additionally, we investigated transmission of
the FMR1 repeat among FXTAS family relatives.
Cases were ascertained from a pool of patients
referred to a reference laboratory in Portugal for genetic
testing for neurological diseases. Inclusion criteria were
as follows: males with onset after age 50 years, absent or
unknown family history of autosomal dominant late-
onset movement disorders, clinical diagnosis of late-
onset movement disorder (spinocerebellar ataxia, SCA;
Huntington disease, HD; or Parkinson disease, PD), and
absence of SCA, HD, or relevant PD mutations. Only
those presenting with ataxia, parkinsonism, and/or cog-
nitive decline were included. Genomic DNA was iso-
lated from peripheral blood using standard techniques.
All patients gave their informed consent. Assessment of
(CGG)n in FMR1 was performed by PCR, improved for
amplification of GC-rich sequence regions, as described
previously [18]. PCR products were visualized on agar-
ose gel stained with ethidium bromide and compared to
a control with 30 CGGs; PCR products that appeared
larger were further analyzed by automated fragment
analysis in a 3730xl DNA Analyzer (Applied Biosystems,
Foster City, CA) for assessment of repeat number. Pre-
mutation status was established for alleles with 55-200
CGGs. Full mutations were detected by double digestion
with EcoRI and EagI of 10 μg of genomic DNA, followed
by electrophoresis in agarose gels and blotting onto
Hybond N+ membranes (Amersham, UK). Probe Ox1.9
was labeled by P32-dCTP nick translation and hybridized
according to standard methodology. Autoradiography
was carried out for 24-48 hours at -70°C, using intensi-
fying screens and Kodak X-Omat-RP films.
A total of 86 male patients were identified as candi-
dates, following application of the defined criteria.
Demographics and clinical features are summarized in
Table 1; 54/86 patients (63%) had ataxia, and 50/86
(58%) had no known family history of late-onset move-
ment disorders. We identified one patient with approxi-
mately 95 CGGs. Frequency of premutations in the total
sample was 1.2%. In the subset of patients with ataxia,
frequency was 1.9%.
The patient carrying the FMR1 premutated allele was
a 73-year-old male, who reported onset at age 51, and
was sent for genetic testing of SCAs (Figure 1). He had
an initial clinical diagnosis of essential tremor that did
not improve upon treatment with beta-blockers and
antiepileptic drugs. Further examination at age 66
revealed a mild cerebellar syndrome with gait ataxia and
dysarthria, difficulties with memory and executive func-
tion, and neurosensorial deafness. MRI showed diffuse
atrophy of the cerebellum and cerebellar peduncles. At
age 72, the patient presented with aggravated cognitive
Table 1 Demographics and clinical features of the patient population
Cardinal clinical feature
Ataxia
(n = 54)
Tremor
(n = 4)
Cognitive deficits
(n = 28)
Total
(N = 86)
Age (mean ± SD) 67.7 ± 9.1 59.0 ± 8.6 70.0 ± 9.2 68.0 ± 9.3
Age-of-onset (mean ± SD) 59.0 ± 6.8 54.0 ± 1.4 60.5 ± 6.7 59.2 ± 6.7
With additional cardinal features (n) 13 1 4 18
Family history (n)
None 33 3 14 50
Unknown 21 1 14 36
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deficits. These clinical features and radiological findings
confirmed a probable FXTAS diagnosis.
After identification of this FXTAS patient, we studied
the family and discovered a clinical history of FXS (Fig-
ure 1) in two first cousins of the proband (IV:5 and
IV:6). Information provided by the proband’s son and by
sisters of the FXS patients also suggests a history of psy-
chiatric disease among premutation-transmitting
females; III:2 had an admission to a psychiatric hospital.
In addition, IV:3 was reported to have a tremor and
cognitive deficits, but no neurological exam or DNA
were available. Consanguinity was present in the family,
thus increasing the risk for genetic diseases. No addi-
tional information was obtained for this family. Two
patients carrying ‘grey zone’ alleles of 49 and 52 repeats
(a frequency of 2.3% in the total sample) were also
found. In the general population, the frequency of grey
zone alleles is 3-4/100 males [16,19].
This study presents the first FXTAS screening in the
Portuguese population of males with adult-onset move-
ment disorders sent for genetic testing. The frequency
of FMR1 premutations was 1.9% (1/54) in patients with
ataxia as the cardinal clinical feature, which is within
the range reported by multiple studies (0% to 4.1%), and
1.2% (1/86) in our global sample. A review of all such
studies (Table 2) shows that the FMR1 premutation rate
among men with cerebellar syndromes averages 1.2%.
Ascertainment of subjects, criteria used and the popula-
tion studied may explain some of the frequency variabil-
ity. As ascertainment via test request for SCA could fail
to detect other FXTAS cases, we also included indivi-
duals referred for testing for PD and HD. We also
applied stringent criteria, as only males with onset
above age 50 years and no suggestive family history of
late-onset movement disorders were included. However,
we found no FMR1 premutations in 32 patients with a
movement disorder other than ataxia, which is consis-
tent with the literature (Table 2). Only 3 premutation
carriers (a rate of 0.3%) have been found in movement
disorder cohorts that exclude ataxia cases - two had an
initial diagnosis of multisystem atrophy (important in
the differential diagnosis of ataxia), while the other was
referred for HD testing.
Our study provides further evidence that a primary
diagnosis of cerebellar ataxia is still the cardinal feature
of the vast majority of FXTAS cases. There has been
II:2
I:1 I:2
II:3 II:4
III:4
II:1
III:3
N/Premutation
(86 CGG)
III:1
IV:1
Premutation
(95 CGG)
IV:2 IV:3 IV:4 IV:5
Full mutation
IV:7
N/N
IV:8
N/N
III:2
IV:6
N/Full mutation
*
*
* ***
FXS
FXTAS
Mental retardation
Psychiatric symptoms
Cognitive impairment
. .
Figure 1 Family pedigree of the FXTAS patient. There is family history of mental retardation in males, and psychiatric disease in females.
Individual IV:3 also presents tremor. Individual IV:4 died in infancy and was never tested for FXS. FMR1 repeat lengths are available for individuals
marked with an asterisk. Symbols with the black circle are obligatory carriers of a FMR1 expanded allele. An arrow indicates the proband. (N,
normal repeat size).
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debate as to whether genetic testing for FXTAS should
be included in screening panels for late-onset movement
disorders. We conclude that, though the prevalence of
FXTAS appears low, genetic testing should be made
available to patients with late-onset movement disorders,
particularly with a clinical diagnosis of ataxia, and in
agreement with the guidelines suggested by Berry-Kravis
et al. [9].
FXTAS appears to be quite rare among women carry-
ing premutations, but a recent study describes a higher
rate of neuropsychiatric symptoms among daughters of
FXTAS patients, including memory and balance pro-
blems, tremor, and psychiatric disturbances [20]. Motor
and mental dysfunction was recently reported in a
FXTAS premutation carrier in a mother-daughter trans-
mission [21]. Another study identified a high lifetime
risk of mood and anxiety disorders among male and
female carriers of the FMR1 premutation [22]. These
findings concur with our observation that, in the family
of the Portuguese FXTAS patient, there is an increased
risk for motor and/or mental dysfunction in relatives
carrying the premutation.
Table 2 Frequency of FMR1 premutations among male patients with adult-onset movement disorders
Sample origin Ascertainment via Inclusion criteria Premutation
rate
Study
United Kingdom Referral for genetic test of SCA Ataxia 2/59 (Macpherson et al., 2003)
[23]
USA Clinical diagnosis of ET ET 0/40 (Garcia Arocena et al., 2004)
[24]
USA Clinical diagnosis of MSA MSA 0/40 (Garland et al., 2004) [25]
USA Referral for genetic test of SCA Ataxia; age > 50 1/167 (Milunsky and Maher 2004)
[26]
Singapore Clinical diagnosis of movement
disorder
ET; age > 45 0/34 (Tan et al., 2004) [27]
Ataxia; isolated 0/30
MSA 0/12
APD 0/15
Japan Clinical diagnosis of MSA MSA 0/36 (Yabe et al., 2004) [28]
Germany Referral for genetic test of SCA Ataxia; AOO > 50 0/269 (Zuhlke et al., 2004) [29]
Europe (mixed) Clinical diagnosis of MSA or related MSA 0/76 (Biancalana et al., 2005) [30]
Ataxia 1/19
Italy Clinical diagnosis of SCA Ataxia 6/275 (Brussino et al., 2005) [31]
Europe (mixed) Clinical diagnosis of MSA MSA* 2/253 (Kamm et al., 2005) [32]
USA Referral for genetic test of SCA and
HD
Cerebellar disease 1/73 (Seixas et al., 2005) [18]
Basal ganglia disease 0/6
Mixed Clinical diagnosis of PD PD 0/414 (Toft et al., 2005) [33]
Belgium Referral for genetic test of SCA Ataxia; age > 50 5/122 (Van Esch et al., 2005) [34]
Spain Clinical diagnosis of SCA Ataxia; isolated; age > 45 1/87 (Rodriguez-Revenga et al.,
2007) [35]
USA Referral for genetic test of SCA Ataxia; age > 50 1/286 (Adams et al., 2008) [17]
Poland Clinical diagnosis of SCA Ataxia; age > 50 1/178 (Rajkiewicz et al., 2008) [36]
Brazil Clinical diagnosis of movement
disorder
Ataxia, and/or tremor, and/or
parkinsonism; age > 45
0/66 (Reis et al., 2008) [37]
Spain Referral for genetic test of HD HD 1/95 (Rodriguez-Revenga et al.,
2008) [38]
United Kingdom Clinical diagnosis of SCA Ataxia 0/105 (Wardle et al., 2009) [39]
Portugal Referral for genetic test of SCA, HD,
and PD
Ataxia; isolated; AOO > 50 1/54 This study
Tremor or cognitive decline 0/32
Total of ataxia
referrals
20/1724
Total of movement disorder referrals (other than ataxia) 3/1119
SCA, spinocerebellar ataxia; ET, essential tremor; MSA, multisystem atrophy; PD, Parkinson disease; APD, atypical Parkinson disease; AOO, age of onset. *Includes
proven, possible, and probable MSA
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In light of this, and given the complex phenotypic
expression of the FMR1 expansions, psychological and
neurologic surveillance (in addition to screening for POI
in females) may be necessary for relatives of FXS and
FXTAS patients, and perhaps for carriers in general.
The complex inheritance and wide spectrum of pheno-
types associated with the FMR1 (CGG)n reinforces the
importance of genetic counseling in these families.
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